Gundling F, Roggenbrod S, Schleifer S, Sohn M, Schepp W
Department of Gastroenterology, Hepatology and Gastrointestinal Oncology, Academic Teaching Hospital Bogenhausen Technical University of Munich Munich Germany.
Department of Visceral Surgery, Academic Teaching Hospital Bogenhausen Technical University of Munich Munich Germany.
Obes Sci Pract. 2018 Nov 28;5(1):68-74. doi: 10.1002/osp4.302. eCollection 2019 Feb.
Fecal microbiota transplantation (FMT) represents a treatment option for some diseases, e.g. recurring Clostridium difficile-associated colitis. However, there is also evidence that FMT can be effective in treating obesity. This pilot study established the approval and willingness of obese patients to undergo FMT.
We conducted a survey of adults with obesity using a questionnaire containing 21 both multiple choice and open questions was dispatched to a cohort of 101 persons with obesity. It included questions aiming at the process of FMT itself, donors as well as possible concerns. Additionally aspects of social background and disease activity were dealt with.
The response rate amounted to 30.1% ( = 31). In our population, mean BMI was 40.5 kg/m while the vast majority already tried out treatment modalities to lose weight before. 25.8% of persons with obesity were aware of FMT. 62.1% were willing to undergo FMT if the donor was healthy and anonymous while only 6.9% clearly refused this option. Sixty preferred an anonymous donor or a person proposed by their doctor while colonoscopy was the preferred application by 76.7%. The absence of risks of the procedure (47.8%) formed the principal motivation while reduction of medication was considered as least important reason (in 26.1). Insufficient testing of the faeces concerning infections raised the most concerns (in 61.6%).
For the majority of the persons with obesity surveyed FMT represents a treatment option. Approximately two thirds of the questionees would consider FMT as an alternative treatment option, even in spite of a satisfactory disease response to current standard therapies. Unsurprisingly there are concerns in regard to the transmission of possible infectious agents as well as to the hygieneic implementation of FMT itself.
粪便微生物群移植(FMT)是某些疾病的一种治疗选择,例如复发性艰难梭菌相关性结肠炎。然而,也有证据表明FMT在治疗肥胖症方面可能有效。这项初步研究确定了肥胖患者接受FMT的认可度和意愿。
我们使用一份包含21个选择题和开放式问题的问卷对成年肥胖患者进行了调查,该问卷被发送给了101名肥胖患者群体。问卷包括针对FMT本身的过程、供体以及可能存在的担忧等问题。此外,还涉及了社会背景和疾病活动方面的内容。
回复率为30.1%(n = 31)。在我们的研究群体中,平均体重指数(BMI)为40.5kg/m²,而绝大多数人此前已经尝试过减肥治疗方法。25.8%的肥胖患者知晓FMT。如果供体健康且匿名,62.1%的人愿意接受FMT,而只有6.9%的人明确拒绝这一选择。60%的人更喜欢匿名供体或医生推荐的人,而76.7%的人更喜欢通过结肠镜检查进行FMT。该手术无风险(47.8%)是主要动机,而减少用药被认为是最不重要的原因(26.1%)。粪便感染检测不足引发了最多担忧(61.6%)。
对于大多数接受调查的肥胖患者来说,FMT是一种治疗选择。即使目前的标准疗法对疾病有令人满意的反应,约三分之二的受访者仍会将FMT视为一种替代治疗选择。不出所料,人们对可能的传染源传播以及FMT本身的卫生实施存在担忧。